CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells.
- Mechanism
- Curator reviewed
CTCE-0214 mimics the activity of the natural chemokine SDF-1 by increasing the level of white blood cells (neutrophils), bleeding prevention cells (platelets) and stem cells (primitive blood forming cells) in the blood. SDF-1 is also believed to work as a traffic controller for infection-fighting white blood cells and progenitor cell migration providing an essential function to combat immunosuppression.
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases.Curator reviewed
- Code names
- CT-0214 · CTCE-0214
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with CTCE-0214, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account